FGFR3 and urinary bladder carcinoma: These MSK-ACCESS specific alterations are likely due in part to the inherent spatial/temporal limitations of tissue profiling, though in some cases it represented acquired drug resistance, such as the identification of FGFR3 point mutations known to confer resistance to FGFR inhibitor therapy in the FGFR3-TACC3 bladder cancers.